BNTX Bathi mangsa ngarep BioNTech Inc.
The high barrier to entry in biopharmaceuticals is driven by colossal R&D costs and stringent patent control. Simultaneously, BioNTech SE (BNTX) is actively developing its portfolio of targeted cancer drugs, as confirmed by the current share value plotted on the GURU.Markets chart, where the indicator stands at 0.16. Its first-mover status in mRNA technology allows BioNTech SE (BNTX) to exercise pricing power amid low demand elasticity.
Rincian analitis perusahaan BioNTech SE
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi pasar:
- informasi kapitalisasi buku:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas BioNTech SE|BNTX - Rasio utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas BioNTech Group|BNTX - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku BioNTech|BNTX - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BioNTech|Rasio cepet biontech.de
- informasi bathi lan kelipatan valuasi:
BNTX - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep BioNTech SE|BNTX - Periode bali modal bisnis|Rega marang bathi mangsa ngarep BioNTech|BNTX - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan BioNTech|BNTX - Bathi operasional sadurunge amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan BioNTech|BNTX - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan biontech.de|BNTX - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep BioNTech SE
Analisis dhasar perusahaan:BNTX, BioNTech SE
To isolate the fundamental stability of BioNTech SE (BNTX) from market noise, it is necessary to analyze expected net income, which aggregates analyst forecasts for future cash flows minus all liabilities. The trend in profit forecasts allows for an assessment of the company's ability to maintain margins amid geopolitical instability affecting cross-border component supplies and the protection of intellectual property.
Perusahaan pesaing
ARGX (argenx SE) - Proyeksi bathi mangsa ngarep|Proyeksi bathi mangsa ngarep Abivax Pharma|Bathi mangsa ngarep ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Penghasilan resik sing dikarepake|Proyeksi bathi mangsa ngarep IMVT (Immunovant Corp)|Prakiraan bathi perusahaan Kiniksa Corp (KNSA)|GRFS - Bathi sing dikarepake|adaptivebiotech.com (ADPT) - Bathi mangsa ngarep|Celldex Therapeutics, Inc. (CLDX) - Bathi sing dikarepake|Bathi mangsa ngarep Aurinia Pharmaceuticals Inc|Bathi mangsa ngarep BCRX|Proyeksi bathi mangsa ngarep Vera Corp|Bathi sing dikarepake Dianthus Therapeutics (DNTH)|pharvaris.com - Prakiraan bathi resik|Proyeksi bathi mangsa ngarep ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Bathi resik sing dikarepake|Intrexon - Proyeksi bathi mangsa ngarep|PHAR: Bathi sing dikarepake|NKTR: Proyeksi bathi mangsa ngarep|UPB - Prakiraan bathi perusahaan|Bathi sing dikarepake Zenas Biopharma|Bathi resik sing dikarepake Immunome Inc IMNM|Bathi sing dikarepake Gossamer Corp (GOSS)|KalVista Corp - Prakiraan bathi resik|Septerna Inc - Bathi mangsa ngarep|Bathi resik mangsa ngarep PVLA (pieris.com)|Savara - Proyeksi bathi mangsa ngarep|Bathi resik sing dikarepake Rigel Pharma|ANAB: Proyeksi bathi mangsa ngarep|Bathi mangsa ngarep Astria Corp|ENGN (enGene Holdings Inc.) - Proyeksi bathi mangsa ngarep|RAPT: Penghasilan resik sing dikarepake|Bathi mangsa ngarep JBIO (Aerovate Therapeutics Inc)|ACRS (Aclaris Therapeutics Inc.) - Penghasilan resik sing dikarepake|Bathi sing dikarepake Kyverna KYTX|Prakiraan bathi perusahaan Tiziana Life Sciences, Ltd. (TLSA)|Cabaletta Bio, Inc. - Proyeksi bathi mangsa ngarep|Bathi resik sing dikarepake ventyxbio.com|THTX: Proyeksi bathi mangsa ngarep|AVTX (Avalo Therapeutics, Inc.) - Bathi sing dikarepake|Bathi sing dikarepake Eledon|Prakiraan bathi resik AGEN (Agenus, Inc)|Bathi mangsa ngarep CLYM (Climb Bio Inc)|Bathi resik mangsa ngarep ZURA|aTyr Pharma - Bathi mangsa ngarep|ADAG: Prakiraan bathi resik|IMA - Bathi sing dikarepake|Bathi forward STTK|EQ: Proyeksi bathi mangsa ngarep|Connect Biopharma Holdings Limited - Penghasilan resik sing dikarepake|IMUX (Immunic Therapeutics) - Proyeksi bathi mangsa ngarep|Proyeksi bathi mangsa ngarep Atara Biotherapeutics Inc|Bathi sing dikarepake InflaRx N.V. (IFRX)|XFOR (X4 Pharmaceuticals, Inc) - Penghasilan resik sing dikarepake|Bathi sing dikarepake Adicet Bio, Inc. ACET|CELU - Bathi mangsa ngarep|INmune Bio - Proyeksi bathi mangsa ngarep|BRNS - Proyeksi bathi mangsa ngarep|KZR (Kezar Life Sciences, Inc) - Bathi mangsa ngarep|SAB Biotherapeutics Inc - Penghasilan resik sing dikarepake|AKTX (Akari Therapeutics) - Proyeksi bathi mangsa ngarep|Enlivex Therapeutics, Ltd. (ENLV) - Prakiraan bathi perusahaan|Bathi sing dikarepake Q32 Bio Inc. (QTTB)|Bathi mangsa ngarep GeoVax Labs GOVX|Bathi sing dikarepake Edesa EDSA|IBIO - Bathi mangsa ngarep|CARM: Bathi mangsa ngarep|XTLB - Proyeksi bathi mangsa ngarep|boltbio.com (BOLT) - Bathi sing dikarepake|Prakiraan bathi resik HCWB|APVO (Aptevo Therapeutics, Inc.) - Proyeksi bathi mangsa ngarep|Bathi resik sing dikarepake aimimmuno.com AIM|Proyeksi bathi mangsa ngarep ADTX|Bathi sing dikarepake GRI (gribio.com)|Proyeksi bathi mangsa ngarep XRTX (XORTX Therapeutics)|Prakiraan bathi perusahaan Vyome Holdings Inc. (HIND)|REVB - Bathi sing dikarepake|Bathi resik sing dikarepake Indaptus Corp|Scinai Immunotherapeutics (SCNI) - Bathi sing dikarepake|Prakiraan bathi resik CALI|Bathi mangsa ngarep AFMD|ALLK (Allakos Therapeutics) - Bathi resik mangsa ngarep|Proyeksi bathi mangsa ngarep HOOK|IGMS - Bathi resik sing dikarepake|Proyeksi bathi mangsa ngarep ITOS (iTeos Therapeutics)|OCEA - Bathi mangsa ngarep|TC BioPharm - Proyeksi bathi mangsa ngarep|Penghasilan resik sing dikarepake THRD (Third Harmonic Bio Inc.)
